RecruitingPhase 2Phase 3NCT06589505
Software as a Medical Device for the Treatment of Patients With PTSD
A Multicenter, Randomized, Double-blind, Parallel-group Comparative Study to Assess Efficacy and Safety of Software as a Medical Device in Patients With Post-Traumatic Stress Disorder (PTSD)
Sponsor
Otsuka Medical Devices Co., Ltd. Japan
Enrollment
52 participants
Start Date
Sep 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the efficacy and safety of Software as a Medical Device in patients with Post-Traumatic Stress Disorder (PTSD)
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria2
- Diagnosis of PTSD according to the DSM-5
- Subjects who are within 1 to 20 years since index trauma
Exclusion Criteria3
- Subjects diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, bipolar I disorder, autism spectrum disorder, or intellectual disability based on DSM-5.
- Subjects diagnosed with any mood disorder and anxiety disorder according to DSM-5 that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgement of the investigator
- Subjects who have completed two or more full courses of trauma-focused therapy in the past
Interventions
DEVICESoftware as a Medical Device
The subject will undergo treatment using the Software as a Medical Device
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06589505
Related Trials
EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study
NCT074470891 location
Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion
NCT074079461 location
Targeted Accelerated TMS for Post-Traumatic Stress Disorder
NCT072456411 location
Building Ukraine's Strength in PTSD Treatment and Research
NCT073181812 locations
Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD
NCT071161091 location